Virtual Breathing Intervention for Enhancing Asthma-related Quality of Life - A Randomized Controlled Trial (BREATHE)
Effectiveness, Feasibility, and Acceptability of a 12-Week Virtual Breathing Training Program to Improve Disease-Specific Quality of Life in Adults With Asthma and Incomplete Symptom Control: A Randomized Controlled Trial
Asthma is a common long-term lung condition that can cause symptoms such as shortness of breath, chest tightness, and anxiety. Even with appropriate medication, about 30-40% of people with asthma do not achieve good symptom control and continue to experience reduced quality of life.
Breathing exercises are recommended as an additional, non-drug treatment for asthma. However, these programs are not widely available outside of rehabilitation clinics, and more scientific evidence is needed, especially for digital formats.
This study aims to investigate whether a 12-week structured breathing training program delivered online can improve asthma-related quality of life in adults whose asthma is not well controlled. Participants will be randomly assigned to either the intervention group or a control group receiving usual care.
The intervention consists of weekly live, group-based breathing sessions led by trained physiotherapists via videoconference, combined with short daily self-practice exercises at home. Participants will also use a simple breathing device to support the exercises. The control group will continue their usual medical care without additional breathing training.
We will assess whether the program improves quality of life, asthma control, and symptoms such as anxiety, stress, and dysfunctional breathing. The study will also evaluate whether the online format is feasible, acceptable, and satisfactory for participants.
The breathing exercises are non-invasive and low risk. The results of this study may help to develop accessible, low-cost, and evidence-based support programs for people with asthma.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Inga Jarosch, Dr.
- Numéro de téléphone: 1730 +49 8652 93
- E-mail: ijarosch@schoen-klinik.de
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged ≥18 years
- Asthma bronchiale
- Partly controlled or uncontrolled asthma according to GINA 2025 criteria
- Access to internet and compatible smartphone for digital intervention and data collection
Exclusion Criteria:
- Clinically relevant nasal obstruction (e.g., severe septal deviation, nasal polyps) affecting nasal breathing
- Current regular use of structured breathing therapy or breathing training devices
- Participation in another interventional clinical trial that may interfere with outcomes
- Severe comorbid conditions limiting participation in mild physical or breathing exercise (e.g., unstable cardiovascular disease)
- Lack of willingness or ability to use required digital tools (video platform, wearable device, smartphone app)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental Group
Virtual Breathing Training Program
|
A 12-week structured, physiotherapist-led breathing training delivered via weekly live video group sessions combined with daily home-based exercises.
The program includes breathing techniques such as nasal breathing, diaphragmatic breathing, and breathing control strategies.
Participants also use a breathing training device to support the exercises.
|
|
Comparateur actif: Usual Care Group
Usual Care
|
Standard medical care for asthma according to current guidelines without additional breathing training intervention.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Asthma-related quality of life (AQLQ)
Délai: Baseline to 12 weeks
|
Change in disease-specific quality of life measured using the Asthma Quality of Life Questionnaire (AQLQ).
The AQLQ is a validated instrument for adults with asthma.
Scores range from 1 to 7, with higher scores indicating better quality of life.
A change of 0.5 points is considered clinically meaningful.
|
Baseline to 12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Asthma Control
Délai: Baseline to 12 weeks (also assessed every 2 weeks)
|
Change in asthma control measured using the Asthma Control Test (ACT).
|
Baseline to 12 weeks (also assessed every 2 weeks)
|
|
Change in Dysfunctional Breathing Symptoms
Délai: Baseline to 12 weeks
|
Change in symptoms of dysfunctional breathing measured by the Nijmegen Questionnaire
|
Baseline to 12 weeks
|
|
Change in Physiological parameters (wearable-derived)
Délai: Baseline to 12 weeks
|
Heart rate, assessed via wearable device.
|
Baseline to 12 weeks
|
|
Change in Physiological parameters (wearable-derived)
Délai: Baseline to 12 weeks
|
Heart rate variability, assessed via wearable device.
|
Baseline to 12 weeks
|
|
Change in Physical Performance
Délai: Baseline and 12 weeks
|
Change in physical performance assessed using the 1-minute sit-to-stand test.
|
Baseline and 12 weeks
|
|
Participant Satisfaction
Délai: At 12 weeks
|
Participant-reported satisfaction with the intervention measured using a study-specific questionnaire (5-point Likert scale).
|
At 12 weeks
|
|
Number of Treatment-related Adverse Events
Délai: Throughout the 12-week study period
|
Incidence of adverse events including dizziness, discomfort, asthma exacerbations, changes in medication use, and use of rescue medication.
|
Throughout the 12-week study period
|
|
Time to Clinically Meaningful Improvement
Délai: Assessed every 2 weeks up to 12 weeks
|
Time to first achievement of a clinically meaningful improvement (≥0.5 points) in AQLQ or ACT.
|
Assessed every 2 weeks up to 12 weeks
|
|
Adherence and Engagement
Délai: 12-week intervention period
|
Attendance at supervised sessions and frequency of home-based breathing exercises (self-reported diary).
|
12-week intervention period
|
|
Change in Psychological outcomes
Délai: Baseline to 12 weeks
|
Changes in anxiety (GAD-7)
|
Baseline to 12 weeks
|
|
Change in Psychological outcomes
Délai: Baseline to 12 weeks
|
Changes in depression (PHQ-9)
|
Baseline to 12 weeks
|
|
Change in Psychological outcomes
Délai: Baseline to 12 weeks
|
Changes in perceived stress (PSS) scores.
|
Baseline to 12 weeks
|
|
Change in Physiological parameters (wearable-derived)
Délai: Baseline to 12 weeks
|
Respiratory rate, assessed via wearable device.
|
Baseline to 12 weeks
|
|
Change in Physiological parameters (wearable-derived)
Délai: Baseline to 12 weeks
|
Sleep duration, assessed via wearable device.
|
Baseline to 12 weeks
|
|
Change in Physiological parameters (wearable-derived)
Délai: Baseline to 12 weeks
|
Daily physical activity (step count), assessed via wearable device.
|
Baseline to 12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- BREATHE
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .